Atrium Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-13.4%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$21.6Mnext fiscal year
FY EPS (est.)
-$3.59next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Atrium Therapeutics Q3 2026 Financial Results | 27 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Delpacibart zotadirsen (del-zota) BLA Submission Timeline QuarterlyTarget: Q1 2026
Annual Collaboration Revenue Annually18.8M
Annual Research and Development (R&D) Expenses Annually16.7M
Watch Items
- Integration of Avidity's late-stage muscle disease pipeline into Novartis's xRNA strategyTrigger: Completion of the $12 billion acquisition transactionAction: Monitor regulatory filings and post-merger operational updates from Novartis
- Clinical progress of delpacibart etedesiran (del-desiran) in Phase 3 HARBOR trial for DM1Trigger: Completion of enrollment and subsequent topline data readoutsAction: Evaluate efficacy and safety data against historical Phase 1/2 MARINA trial results
- Spin-off of early-stage precision cardiology programs into Atrium TherapeuticsTrigger: Launch of Atrium Therapeutics under the Nasdaq ticker $RNA with $270 million in fundingAction: Track IND filings for PRKAG2 syndrome treatment in H2 2026 and PLN cardiomyopathy in 2027
Research as of 19 Jun 2026